These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36297659)

  • 1. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells.
    Camorani S; Tortorella S; Agnello L; Spanu C; d'Argenio A; Nilo R; Zannetti A; Locatelli E; Fedele M; Comes Franchini M; Cerchia L
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.
    Agnello L; Tortorella S; d'Argenio A; Carbone C; Camorani S; Locatelli E; Auletta L; Sorrentino D; Fedele M; Zannetti A; Franchini MC; Cerchia L
    J Exp Clin Cancer Res; 2021 Jul; 40(1):239. PubMed ID: 34294133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
    Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
    Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation.
    Duan T; Xu Z; Sun F; Wang Y; Zhang J; Luo C; Wang M
    Biomed Pharmacother; 2019 Sep; 117():109121. PubMed ID: 31252265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy.
    Lv H; Wang T; Ma F; Zhang K; Gao T; Pei R; Zhang Y
    Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
    Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
    Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation.
    Pacheco-Torres J; Penet MF; Krishnamachary B; Mironchik Y; Chen Z; Bhujwalla ZM
    Front Oncol; 2020; 10():614365. PubMed ID: 33718115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
    Liu CW; Lin WJ
    J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies.
    Camorani S; Caliendo A; Morrone E; Agnello L; Martini M; Cantile M; Cerrone M; Zannetti A; La Deda M; Fedele M; Ricciardi L; Cerchia L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):92. PubMed ID: 38532439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.